S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
Log in
NASDAQ:NH

NantHealth Stock Forecast, Price & News

$2.30
-0.05 (-2.13 %)
(As of 11/25/2020 05:07 PM ET)
Add
Compare
Today's Range
$2.25
Now: $2.30
$2.38
50-Day Range
$1.96
MA: $2.25
$2.49
52-Week Range
$0.81
Now: $2.30
$6.39
Volume121,289 shs
Average Volume517,401 shs
Market Capitalization$255.79 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company converging science and technology in the United States, the United Kingdom, Singapore, and Canada. It provides NantHealth solutions, including molecular profiling solutions, software-as-a-service platforms, and connected care medical device interoperability solutions to enable value-based care and evidence-based clinical practice. The company's products include GPS Cancer, a molecular profile that integrates whole genome/exome sequencing of tumor and normal germline samples, as well as whole transcriptome sequencing; GPS Cancer Report, a GPS cancer solution; Liquid GPS, a blood-based molecular laboratory test that provides a tool for noninvasive tumor profiling and quantitative monitoring of treatment response; and Eviti, a decision support solution that provides evidence-based clinical decision support. It also offers web-based and mobile software solutions, such as Device Connectivity Suite, a device connectivity and near real-time biometric software and hardware suite to aggregate data from in-hospital and remote medical devices. In addition, NantHealth, Inc. provides NaviNet Open, a payer-provider collaboration platform comprising plan central, eligibility and benefit, claims status inquiry, claims management, referral, authorization, and document exchange, as well as AllPayer Access services; and systems infrastructure solutions, which include cloud computing, storage, and transport infrastructure. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was founded in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.
Read More
NantHealth logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Industry, Sector and Symbol

Industry Data processing & preparation
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone310-883-1300
Employees398

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$95.96 million
Book Value($0.52) per share

Profitability

Net Income$-62,760,000.00

Miscellaneous

Market Cap$255.79 million
Next Earnings Date2/26/2021 (Estimated)
OptionableOptionable
$2.30
-0.05 (-2.13 %)
(As of 11/25/2020 05:07 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NH News and Ratings via Email

Sign-up to receive the latest news and ratings for NH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NantHealth (NASDAQ:NH) Frequently Asked Questions

How has NantHealth's stock price been impacted by Coronavirus?

NantHealth's stock was trading at $1.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NH stock has increased by 27.1% and is now trading at $2.30.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than NantHealth?

Wall Street analysts have given NantHealth a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NantHealth wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NantHealth's next earnings date?

NantHealth is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for NantHealth
.

How were NantHealth's earnings last quarter?

NantHealth, Inc. (NASDAQ:NH) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The business earned $18.77 million during the quarter, compared to analysts' expectations of $18.70 million.
View NantHealth's earnings history
.

Who are some of NantHealth's key competitors?

What other stocks do shareholders of NantHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NantHealth investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Micron Technology (MU), NantKwest (NK), AbbVie (ABBV), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH) and Netflix (NFLX).

Who are NantHealth's key executives?

NantHealth's management team includes the following people:
  • Dr. Patrick Soon-Shiong F.A.C.S., M.Sc., FRCS (C), M.D., FACS, Founder, Chairman & CEO (Age 67)
  • Mr. Bob Petrou, Chief Financial Officer (Age 48, Pay $507.09k)
  • Mr. Ronald Allen Louks, Chief Operating Officer (Age 55, Pay $751.98k)
  • Mr. Brandon Villery, Sr. VP & Gen. Counsel
  • Mr. Mark Mozley, Sr. VP of Global Sales & Marketing
  • Ms. Maureen Becker, Sr. VP of HR
  • Dr. Sandeep K. Reddy M.D., Chief Medical Officer
  • Mr. Keith Krebs, Sr. VP of Client Services
  • Mr. Chris House, Sr. VP of Product Management & Devel.

When did NantHealth IPO?

(NH) raised $91 million in an IPO on Thursday, June 2nd 2016. The company issued 6,500,000 shares at a price of $12.50-$15.50 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and First Analysis Securities, Canaccord Genuity and FBR were co-managers.

What is NantHealth's stock symbol?

NantHealth trades on the NASDAQ under the ticker symbol "NH."

Who are NantHealth's major shareholders?

NantHealth's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.21%), State Street Corp (0.38%), AQR Capital Management LLC (0.33%), Arrowstreet Capital Limited Partnership (0.24%), Morgan Stanley (0.10%) and California Public Employees Retirement System (0.05%).
View institutional ownership trends for NantHealth
.

Which institutional investors are selling NantHealth stock?

NH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Jane Street Group LLC.
View insider buying and selling activity for NantHealth
.

Which institutional investors are buying NantHealth stock?

NH stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Arrowstreet Capital Limited Partnership, Morgan Stanley, California Public Employees Retirement System, GSA Capital Partners LLP, Acadian Asset Management LLC, Squarepoint Ops LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for NantHealth
.

How do I buy shares of NantHealth?

Shares of NH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NantHealth's stock price today?

One share of NH stock can currently be purchased for approximately $2.30.

How big of a company is NantHealth?

NantHealth has a market capitalization of $255.79 million and generates $95.96 million in revenue each year. The company earns $-62,760,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. NantHealth employs 398 workers across the globe.

What is NantHealth's official website?

The official website for NantHealth is www.nanthealth.com.

How can I contact NantHealth?

NantHealth's mailing address is 9920 JEFFERSON BLVD, CULVER CITY CA, 90232. The company can be reached via phone at 310-883-1300 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.